1Sotiriou C,Pusztai L.Gene-expression signatures in breast cancer[J].N Engl J Med,2009,360(8):790-800.
2Perou CM,Serlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406 (6797):747-752.
3Desmedt C,Haibe Kains B,Wirapati P,et al.Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes[J].Clin Cancer Res,2008,14(16):5158-5165.
4Hugh J,Hanson J,Cheang MC,et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 Trial[J].J Clin Oncol,2009,27(8):1168-1176.
5Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
6Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25 (1):118-145.
7Hammond ME,Hayes DF,Wolff AC.Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER-2 testing in breast cancer[J].J Clin Oncol,2011,29 (15):e458.
8Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011.doi:10.1093/annonc/mdr304.
9Giuliano AE,Hunt KK,Ballman KV,et al.Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial[J].JAMA,2011,305(6):569-575.
10Swain SM,Jeong JH,Wolmark N.Amenorrhea from breast cancer therapy-not a matter of dose[J].N Engl J Med,2010,363(23):2268-2270.
